




FIG. 1A




FIG. 1B




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 2D

IL-1R1Acq_ECD




FIG. 2D (Cont. 1)

IL-1R1Acp_ECD




FIG. 2D (Cont. 2)

IL-1R1Acp_ECD




FIG. 2D (Cont. 3)





FIG. 2D (Cont. 4)

IL-1R1Acp_ECD



IL-1R1Acp_ECD

FIG. 2D (Cont. 5)




FIG. 2D (Cont. 6)




FIG. 2D (Cont. 7)

IL-1R1Acp_ECD




FIG. 2D (Cont. 8)

IL-1R1Acp_ECD




FIG. 2D (Cont. 10)




FIG. 2D (Cont. 11)




FIG. 2E




FIG. 2E (Cont. 1)




FIG. 2E (Cont. 2)




FIG. 2F




FIG. 2G




FIG. 2G (Cont. 1)




FIG. 2G (Cont. 2)




FIG. 2H




FIG. 2H (Cont. 1)




FIG. 2H (Cont. 2)




FIG. 2I




FIG. 2I (Cont. 1)




FIG. 2I (Cont. 2)

28 / 56

Linked cytokine antagonists




FIG. 3A




FIG. 3B




FIG. 3C

29 / 56




FIG. 3D




FIG. 3E




FIG. 3F




FIG. 4A

31 / 56




FIG. 4B

SUBSTITUTE SHEET (RULE 26)

32 / 56




FIG. 4C






FIG. 4D








FIG. 5B (Cont.)




FIG. 5C




FIG. 5C (Cont.)




FIG. 6A




FIG. 6B




FIG. 6C




FIG. 6D

39 / 56




FIG. 6E





FIG. 6F



IL-1R1 → FIG. 6F (Cont.)

42 / 56




FIG. 6G

43 / 56




FIG. 7A




FIG. 7B

45 / 56




FIG. 7C




FIG. 9

Trimeric synthekine exhibits a different signaling activation profile than their wt counterparts:




FIG. 10




FIG. 11




FIG. 12

51 / 56




FIG. 12 (Cont.)

Trimeric syntheanine differentiated DCs exhibit high degree of phagocytosis:





FIG. 13



Trimeric syntheKine differentiated DCs exhibit different differentiation markers:






FIG. 15



mIL4DN-mIFN β DN2 synthekine

sig peptide

mIL4 DN

mIL4 DN

mIL4 DN

linker

mIFN β DN2

mIFN β DN2

mIFN β DN2

6xHis

MKTIIALSYIFCLVFAGSHIHGCDKNHLLREIIIGILNEVTGEGTPTCTEMDVPNVLT

ATKNTSELVCRASKVLRIFYLKHGKTPCLKKNSSVLMELQRLFRALRCLDSSI

SCTMNEKSTSLKDFLESLSKSIMDDDDSGSGGINYKQLQLQERTNIAKCQEL


LEQLNGKINATYAADFKIPMENTEKMQKSYTAFAIQEMLQNVFLVFRNNESS

TGWNETIVVRLLEDLHQQTVFLKTVLEEKQEEERLTWEMSS TALHLKSYWVRV

QRYLKLKMKYNSYAWMVVRAEII FANFLIIIRRLTRNFQAAAAHHHHH

mIL4DN: Q116D, Y119D

mIFN β DN2: R15A, L30A, R33A, R147A



	mIFNb	mIFNbDN2	mIL4	mIL4 DN	mIL4DN/bDN2	mIL4+mIFNb
EC50	1.238	0.00625	0.02362	0.007153	0.1595	0.05851

FIG. 17